LRA-Genentech Award on Immune Resetting Therapies for Lupus

LRA-Genentech Award on Immune Resetting Therapies for Lupus

Helps yr for pilot or mechanistic immune resetting research in lupus co-funded through the LRAGenentech Award on Immune Resetting Therapies for.

The LRA-Genentech Award on Immune Resetting Therapies for Lupus is a co-funded grant program supported by the Lupus Research Alliance (LRA) and Genentech, a leading biopharmaceutical company. The LRA, a New York 501(c)(3) (Federal Tax ID #58-2492929) with over $284 million distributed across 675+ grants, identified immune resetting as a core strategic priority in its 2024–2028 Research Roadmap, which explicitly calls for accelerating immune resetting treatments that are cost-effective and reduce patient burden and risk. The Genentech partnership provides industry co-funding alongside LRA's nonprofit grant infrastructure for this specific therapeutic category.

The award funds two distinct tracks at up to $150,000 per year: a one-year pilot project focused on novel technologies or methodologies to achieve immune resetting in lupus, or a two-year mechanistic research project aimed at deepening understanding of current or emerging immune resetting therapies. Total awards therefore range from $150,000 (one-year pilot) to $300,000 (two-year mechanistic track). Eligible applicants are universities and nonprofit research organizations; for-profit applicants are ineligible as lead institutions. The 2026 cycle deadline has passed; the 2027 cycle is anticipated given the program's inclusion in the LRA's active grant portfolio. Scientific inquiries go to Maya Bader, PhD, at mbader@lupusresearch.org; administrative inquiries to Diomaris Gonzalez at dgonzalez@lupusresearch.org.

For immunologists and clinical researchers working on B-cell depletion, regulatory T-cell restoration, or other immune resetting strategies in lupus or related autoimmune diseases, this award offers a clearly scoped, well-resourced mechanism. The presence of Genentech as co-funder signals industry interest in the research agenda; applicants should be aware that IP terms are not publicly published and may be addressed in the RFA. The pilot track ($150K, one year) is well suited for investigators developing or validating a new technology platform, while the mechanistic track ($300K, two years) fits those extending existing clinical data into biological mechanism.